DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1726 resistance against anticancer nucleosides. Mol Cancer Ther,
2008, 7:3092–3102.
DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue
after high-dose methotrexate. J Clin Oncol, 1996,
14:2145–2149.
Deyoung MP, Ellisen LW. p63 and p73 in human cancer:
Defining the network. Oncogene, 2007, 26:5169–5183.
Dolan S, Fitch M. The management of venous thromboembolism
in cancer patients. Br J Nurs, 2007, 16:1308–1312.
Dorr RT. New findings in the pharmacokinetic, metabolic, and
drug-resistance aspects of mitomycin C. Semin Oncol, 1988,
15:32–41.
Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance
transporter from human MCF-7 breast cancer cells. Proc Natl
Acad Sci U S A, 1998, 95:15665–15670.
Drumea K, Yang ZF, Rosmarin A. Retinoic acid signaling in
myelopoiesis. Curr Opin Hematol, 2008, 15:37–41.
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat
(suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous
T-cell lymphoma (CTCL). Blood, 2007, 109:31–39.
Endicott JA, Ling V. The biochemistry of P-glycoprotein–
mediated multidrug resistance. Annu Rev Biochem, 1989,
58:137–171.
Farber S, Diamond LK, Mercer RD, et al. Temporary remissions
in acute leukemia in children produced by folic antagonist
4-amethopteroylglutamic acid (aminopterin). N Engl J Med,
1948, 238:787–793.
Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5
fluorouracil-folinic acid combination on respective
intracellular determinants of drug activity. Br J Cancer, 2002,
86:1162–1168.
Flanagan SA, Robinson BW, Krokosky CM, Shewach DS.
Mismatched nucleotides as the lesions responsible for
radiosensitization with gemcitabine: A new paradigm for
antimetabolite radiosensitizers. Mol Cancer Ther, 2007,
6:1858–1868.
Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine
plus cyclophosphamide in elderly patients with untreated and
relapsed or refractory chronic lymphocytic leukaemia.
Hematol Oncol, 2008, 26:247–251.
Forghieri F, Luppi M, Morselli M, Potenza L. Cytarabine-related
lung infiltrates on high resolution computerized tomography:
A possible complication with benign outcome in leukemic
patients. Haematologica, 2007, 92:e85–e90.
Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic
study of arsenic trioxide in children and adolescents
with refractory or relapsed acute leukemia, including
acute promyelocytic leukemia or lymphoma. Blood, 2008,
111:566–573.
Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the
CD95 (APO-1/FAS) receptor/ligand system in drug-induced
apoptosis in leukemia cells. Nat Med, 1996, 2:574–577.
Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-
11, a new derivative of camptothecin, for previously untreated
non-small-cell lung cancer. J Clin Oncol, 1992, 10:16–20.
Gallagher RE. Retinoic acid resistance in acute promyelocytic
leukemia. Leukemia, 2002, 16:1940–1958.
Gandhi V. Questions about gemcitabine dose rate: Answered or
unanswered? J Clin Oncol, 2007, 25:5691–5694.
Garcia ST, McQuillan A, Panasci L. Correlation between the cytotoxicity
of melphalan and DNA crosslinks as detected by the
SECTION VIII
CHEMOTHERAPY OF NEOPLASTIC DISEASES
ethidium bromide fluorescence assay in the F 1
variant of B 16
melanoma cells. Biochem Pharmacol, 1988, 37:3189–3192.
Gardner ER, Dahut WL, Scripture CD, et al. Randomized
crossover pharmacokinetic study of solvent-based paclitaxel
and nabpaclitaxel. Clin Cancer Res, 2008, 14:4200–4205.
Gerth K, Bedorf N, Höfle G, et al. Epothilons A and B:
Antifungal and cytotoxic compounds from Sorangium cellulosum
(Myxobacteria). Production, physico-chemical and biological
properties. J Antibiot (Tokyo), 1996, 49:560–563.
Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and
pharmacokinetic study of irinotecan in adults with recurrent
malignant glioma. Clin Cancer Res, 2003, 9:2940–2949.
Gilman A, Philips FS. The biological actions and therapeutic
applications of the β-chlorethylamines and sulfides. Science,
1946, 103:409–415.
Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis
of human equilibrative nucleoside transporter-1 predicts
survival in pancreas cancer patients treated with gemcitabine.
Cancer Res, 2006, 66:3928–3935.
Go RS, Adjei AA. Review of the comparative pharmacology and
clinical activity of cisplatin and carboplatin. J Clin Oncol,
1999, 17:409–422.
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of
nanoparticle albumin-bound paclitaxel compared with polyethylated
castor oil-based paclitaxel in women with breast cancer.
J Clin Oncol, 2005, 23:7794–7803.
Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid
liposarcomas (MLS): A long-term analysis of a single-institution
series. Ann Oncol, 2009, 20:1439–1444.
Grever MR, Doan CA, Kraut EH. Pentostatin in the treatment of
hairy-cell leukemia. Best Pract Res Clin Haematol, 2003,
16:91–99.
Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis
B with temozolomide. N Engl J Med, 2007, 356:1591–1592.
Grochow LB. Busulfan disposition: The role of therapeutic monitoring
in bone marrow transplantation induction regimens.
Semin Oncol, 1993, 20:18–25.
Grogan L, Sotos GA, Allegra CJ. Leucovorin modulation of fluorouracil.
Oncology (Williston Park), 1993, 7:63–72; discussion
75–76.
Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the
mechanisms and management of drug-induced QT prolongation
and torsade de pointes. Am Heart J, 2007, 153:891–899.
Hausknecht RU. Methotrexate and misoprostol to terminate early
pregnancy. N Engl J Med, 1995, 333:537–540.
Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics
after intensive polyethylene glycol-conjugated
L-asparaginase therapy for children with relapsed acute lymphoblastic
leukemia. Clin Cancer Res, 2004, 10:5335–5341.
He X, Batchelor TT, Grossman S, et al. Determination of procarbazine
in human plasma by liquid chromatography with electrospray
ionization mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci, 2004, 799:281–291.
Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine
methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to
modulate MGMT activity. J Clin Oncol, 2008, 26:4189–4199.
Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison
of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine
and 1-β-D-arabinofuranosylcytosine. Cancer
Res, 1988, 48:4024–4031.